Altis Labs raises $25M Series A for AI clinical trial endpoint

Funding for AI-driven clinical trial endpoint analysis could accelerate drug development but carries risks of over-reliance on unvalidated AI in medical research.

Auto-scored: A funding round for AI in clinical trials is a minor risk and a partial mitigation step for medical AI development.